Literature DB >> 1606396

Home intravenous antibiotic treatment of patients with cystic fibrosis.

B Strandvik1, L Hjelte, A S Malmborg, B Widén.   

Abstract

We report one-year's experience of home iv antibiotic treatment in 31 patients with cystic fibrosis chronically colonized with Pseudomonas aeruginosa. The patients were aged 4-67 years and had a mild to severe disease as indicated by a Shwachman score of 46-95 (mean 77). Ninety-two courses of iv antibiotic therapy were given (mean 3.0 per patient). The mean duration of the courses was 15.4 days. The entire antibiotic course, except for the first dose, was administered at home in 70% of the courses. Most patients (94%) were given a combined treatment of a beta-lactam and an aminoglycoside, administered by the patients themselves or their parents. One inserted venous cannula could be used for the whole treatment period in 30% of the courses. There were no complications. The clinical and bacteriological outcome was good to excellent in 89% of the courses, with temporary eradication or semi-quantitative decrease of Pseudomonas growth in sputum. Lung function (forced expiratory volume at 1 s) and blood gases improved significantly (p less than 0.001) and p less than 0.01, respectively). Most patients were able to attend work or school as usual, and 96% of the patients preferred this type of treatment to hospitalization. Apart from the psychosocial advantages, the economical savings were substantial. In comparison to traditional treatments in hospital (21 patients, 41 courses) home iv antibiotic treatment was safe and effective.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606396     DOI: 10.1111/j.1651-2227.1992.tb12239.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  19 in total

1.  Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.

Authors:  J Michael Collaco; Deanna M Green; Garry R Cutting; Kathleen M Naughton; Peter J Mogayzel
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

2.  Home intravenous anti-infective therapy (HIVAT): do the benefits outweigh the risks?

Authors:  D N Williams
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

3.  Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1.

Authors:  M F Wildhagen; J B Verheij; J G Verzijl; H B Hilderink; L Kooij; T Tijmstra; L P ten Kate; J Gerritsen; W Bakker; J D Habbema; F Habbema
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

4.  An audit of the effect of intravenous antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis.

Authors:  J M Bradley; E S Wallace; J S Elborn; J L Howard; M P McCoy
Journal:  Ir J Med Sci       Date:  1999 Jan-Mar       Impact factor: 1.568

5.  [Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study].

Authors:  C Krauth; R Busse; C Smaczny; G Ullrich; T O Wagner; J Weber; T Welte
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 6.  Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages.

Authors:  S Esposito
Journal:  Drugs       Date:  2000       Impact factor: 9.546

7.  Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.

Authors:  P Vic; S Ategbo; D Turck; M O Husson; V Launay; G A Loeuille; A Sardet; A Deschildre; D Druon; C Arrouet-Lagande
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

Review 8.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.

Authors:  Janice Abbott; Louise Gee
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis - Is it good for the patient?

Authors:  Iara Maria Sequeiros; Nabil A Jarad
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.